Navigation Links
Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

cipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen's ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen's management
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today it has completed enrollment ... Data Review Committee (DRC) earlier this year, into ... is a first-in-class innate defense regulator (IDR) and ...
(Date:8/31/2015)... STAMFORD, Conn. , Aug. 31, 2015 /PRNewswire/ ... Ltd., and Purdue Pharma L.P. announced today that they ... development and commercialization of Eisai,s clinical candidate lemborexant (development ... III clinical development for the treatment of insomnia. ... and Purdue Pharma will share the costs of lemborexant ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( ... "Prescription Pain Drugs - Including Opioid, Anticonvulsant, ... Markets, Competitors and Opportunities: 2015 - 2020 Analysis ... Pain is defined as an unpleasant ... potential tissue damage. At some point, everyone experiences ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... PA (PRWEB) , ... August 31, 2015 , ... ... than their peers may be at a greater risk for injury, potentially because ... behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now ... Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. He ... studies at the University of California, Irvine Medical School. As a nationally recognized Regents ...
(Date:8/31/2015)... ... 2015 , ... The German soccer league (DFL Digital Sports) ... make website updates quicker and more flexible. The company's CMS solution FirstSpirit is ... German equivalent of the U.S. Soccer Federation) more modern, exciting and interactive for ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While working as an ... effectively deliver oxygen with a lower risk of failure," explained an inventor, from ... the Adam Device." , The Adam Device offers a quick, effective and predictable ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2
... Operations of Grady Memorial Hospital, ATLANTA, Dec. 13 ... $100,000 to the Henry W. Grady Health System,Foundation. The ... Grady Memorial,Hospital, which plays a pivotal role in bringing ... AMERIGROUP Foundation is affiliated with AMERIGROUP Community Care,of Georgia, ...
... targeted treatments for leukemia, bone marrow transplants , THURSDAY, ... human blood cells has been identified by Stanford University ... treatments for blood cancers and other blood diseases. , ... the initial offspring of a blood-forming stem cell in ...
... DALLAS and LONDON, Dec. 13 U.S. ... first network focused on prevention in the,United ... it has signed a letter of intent ... preventive medicine businesses in the United Kingdom.,iHealth ...
... and 14 Walkouts at Thirteen ... Facilities, ... facilities throughout Northern California are,preparing for their second strike against the healthcare ... patient care and,patient safety. Sutter has threatened a lockout at the majority ...
... Speaker Nancy Pelosi,Majority Leader Steny Hoyer, Majority Whip James ... news conference late this afternoon in,the Capitol on the ... the bill. Below are the Speaker,s opening remarks:, ... the President,will veto the SCHIP bill. Once again, he ...
... creams, supplements and plastic surgery to look younger if they ... , A study of 297 women aged from 27 to ... with special diets, vitamins, creams, Botox or plastic surgery if ... look significantly younger. , The researchers, Professor Brett Martin ...
Cached Medicine News:Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 2Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 3Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 2Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 3Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 2Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 3Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Women persist in plastic surgery treatments that are not working, research says 2
... Suture™ POLY GIA™ 75-.060 single use ... rows of LACTOMER™ absorbable copolymer staples ... the two, double rows., ,The ... use surgical stapler has application in ...
... Single Use Loading Units ... with ILA™ 75 (Single Use ... ,INDICATIONS The ILA™ 75 ... designed for use in the ...
... Reloadable Staplers and the SGIA™ Knifeless ... pediatric and thoracic surgical procedures for ... , ,The Auto Suture™ GIA™ ... Stapler have application in abdominal, gynecological, ...
... anastomotic staplers available in four sizes to ... diameter. The staplers permit tissue attachment to ... and ease of use. The instruments allow ... adjusting the height of the closed staple. ...
Medicine Products: